

Pueraria, Pueraria root, Radix puerariae, Ge Gen, Kudsu, Japanese arrowroot
Kudzu is a botanical used in Chinese medicine to treat alcoholism, menopausal symptoms, diabetes mellitus, fever, common cold, and neck or eye pain. There are several species of Kudzu and both the flowers and root extract are used for their medicinal properties. Isoflavones, the major components of kudzu, are thought responsible for the beneficial effects.
Kudzu demonstrated antiproliferative (1), anti-inflammatory (3), and neuroprotective (16) properties. It also has antiapoptotic effects against ethanol-induced apoptosis and suppresses alcohol intake (4) (9).
Data from clinical trials suggest that kudzu can improve symptoms such as hot flushes and night sweats in perimenopausal women (5) (10) and cognitive function in postmenopausal women (6). Because Kudzu has estrogenic effects (11), individuals with hormone-sensitive cancers and those taking tamoxifen should avoid it.
Tectorigenin, an isoflavone present in kudzu, demonstrated antiproliferative activity against human cancer (HL-60) cells. The proposed mechanisms are induction of differentiation in the cells and a reduction in the expression of Bcl-2, an antiapoptotic protein (1). In addition, isoflavones in Pueraria mirifica are thought to be involved in alleviating symptoms such as hot flashes and night sweats in perimenopausal women (5) and affect cognitive function in postmenopausal women (6). The isoflavones present in kudzu root extract are also thought to suppress alcohol intake and alcohol withdrawal symptoms in mice although the mechanism is unclear (4). The anti-inflammatory property of kudzu is attributed to its ability to decrease Prostaglandin E2 and tumor necrosis factor (TNF)-alpha release, both of which are involved in inflammatory process (3). The flowers of Pueraria thunbergiana exhibit protective effects against ethanol-induced apoptosis in human neuroblastoma cells by inhibiting the expression of a protease, caspase-3 that is responsible for proteolytic cleavage of many proteins (7).
The pharmacokinetics of puerarin, the major isoflavone present in kudzu were determined in healthy adults. Following repeated administration of kudzu extract, puerarin was found to be rapidly absorbed via the oral route, reaching peak levels at 2 hours. It had a half-life of approximately 4.3 hours. The elimination half-life was not significantly altered after repeated administration (12).
Woo J, et al. Comparison of Pueraria lobata with hormone replacement therapy in treating the adverse health consequences of menopause. Menopause 2003; 10(4):352-361.
In this study, 127 postmenopausal women were randomized to receive hormone replacement therapy, Pueraria lobata (equivalent of 100mg isoflavone), or no treatment for three months. Lipid profile, neuropsychological tests and the levels of luteinizing hormone and follicle-stimulating hormone were measured at baseline and after three months. Women who received Pueraria showed no changes in lipid profile compared to those in HRT group who showed a reduction in cholesterol and LDL cholesterol. There was no significant change in hormonal levels in the Pueraria group compared to controls. However, women in Peuraria group showed improvement in flexible thinking whereas those in the HRT group demonstrated improved delayed recall. Although the study did not establish any use of Pueraria for controlling menopausal symptoms, it seems to affect cognitive function. Further studies are warranted.
Bottom Line: Kudzu has not been shown to treat cancer in humans.
Kudzu is an herb used in Chinese medicine to treat alcoholism, menopausal symptoms, diabetes mellitus, fever, common cold, and neck or eye pain. In vitro studies have shown that kudzu has antiproliferative, anti-inflammatory properties. It also suppressed alcohol intake. One clinical trial showed that kudzu may affect cognitive function in postmenopausal women. Patients with estrogen receptor-positive breast cancers should discuss with their physicians before using kudzu as isoflavones can promote the growth of certain breast cancer cells.
Menopause:
In this clinical trial 127 postmenopausal women were given hormone replacement therapy (HRT), Pueraria lobata (equivalent of 100mg isoflavone), or no treatment for three months. There were no changes in hormonal levels in any of the groups. Women who took HRT had lowered cholesterol and LDL cholesterol levels compared to those on Pueraria. But women in Pueraria group showed improvement in flexible thinking and those in HRT group demonstrated improved delayed recall. Pueraria may have an effect on cognitive function in postmenopausal women.